These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 23371856)

  • 1. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
    Arcila ME; Nafa K; Chaft JE; Rekhtman N; Lau C; Reva BA; Zakowski MF; Kris MG; Ladanyi M
    Mol Cancer Ther; 2013 Feb; 12(2):220-9. PubMed ID: 23371856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
    Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S490-6. PubMed ID: 24419753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
    Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
    J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
    Naidoo J; Sima CS; Rodriguez K; Busby N; Nafa K; Ladanyi M; Riely GJ; Kris MG; Arcila ME; Yu HA
    Cancer; 2015 Sep; 121(18):3212-3220. PubMed ID: 26096453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
    He M; Capelletti M; Nafa K; Yun CH; Arcila ME; Miller VA; Ginsberg MS; Zhao B; Kris MG; Eck MJ; Jänne PA; Ladanyi M; Oxnard GR
    Clin Cancer Res; 2012 Mar; 18(6):1790-7. PubMed ID: 22190593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).
    Cardona AF; Rojas L; Zatarain-Barrón ZL; Freitas HC; Granados ST; Castillo O; Oblitas G; Corrales L; Castro CD; Ruiz-Patiño A; Martín C; Pérez MA; González L; Chirinos L; Vargas C; Carranza H; Otero J; Rodriguez J; Rodriguez J; Archila P; Lema M; Acosta Madiedo J; Karachaliu N; Wills B; Pino LE; de Lima V; Rosell R; Arrieta O;
    Lung Cancer; 2018 Nov; 125():265-272. PubMed ID: 30429031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.
    Hosgood HD; Pao W; Rothman N; Hu W; Pan YH; Kuchinsky K; Jones KD; Xu J; Vermeulen R; Simko J; Lan Q
    Respir Med; 2013 Nov; 107(11):1755-62. PubMed ID: 24055406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
    Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
    Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
    Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.
    Cheng C; Wang R; Li Y; Pan Y; Zhang Y; Li H; Zheng D; Zheng S; Shen X; Sun Y; Chen H
    Sci Rep; 2015 Sep; 5():13959. PubMed ID: 26354324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
    J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Yu S; Zheng D; Zhao Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
    Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
    Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.